Influences of everninomicin, vancomycin and teicoplanin on chemical mediator release from rat peritoneal mast cells

Japanese Journal of Pharmacology

Volumn 83, Issue 4, 2000, Pages 300-305

  Sugimoto, Y ^a   Iba, Y ^a   Utsugi, K ^a   Kamei, C ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Everninomicin; Histamine release; Prostaglandin D2 release; Teicoplanin; Vancomycin

Indexed keywords

CONCANAVALIN A; EVERNINOMICIN; HISTAMINE; PROSTAGLANDIN D2; TEICOPLANIN; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; ENZYME RELEASE; HISTAMINE RELEASE; IN VITRO STUDY; MALE; MEDIATOR; MEDIATOR RELEASE; NONHUMAN; PERITONEUM MAST CELL; PROSTAGLANDIN RELEASE; RAT;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ASCITIC FLUID; CONCANAVALIN A; HISTAMINE RELEASE; MALE; MAST CELLS; PROSTAGLANDIN D2; RATS; RATS, WISTAR; TEICOPLANIN; VANCOMYCIN;

EID: 0033817268     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.83.300     Document Type: Article

References (30)

1. Everninomicin, a new oligosaccharide antibiotic: Its antimicrobial activity, post-antibiotic effect and synergistic bactericidal activity
2. Vancomycin: A reappraisal
3. Teicoplanin revisited
4. Adverse effects of vancomycin administered in the perioperative period
5. Histamine release by vancomycin: A mechanism for hypotension in man
6. Vancomycin and the red man syndrome: Pharmacodynamics of histamine release
7. Comparison of vancomycin- and teicoplanin-induced histamine release and red man syndrome
8. Anaphylactoid reactions to glycopeptide antibiotics
9. Absence of 'red man syndrome' in patients being treated with vancomycin or high-dose teicoplanin
10. Phase I clinical study on teicoplanin and investigation of its histamine-releasing action
11. Comparative safety of teicoplanin and vancomycin
12. Red man syndrome with teicoplanin
13. A multicentre open clinical trial of teicoplanin in infections caused by Gram-positive bacteria
14. A risk-benefit assessment of teicoplanin in the treatment of infections
15. + pump activity in rat peritoneal mast cells: Inhibition by extracellular calcium
16. Modulation of histamine secretion from concanavalin A-activated rat mast cells by phosphatidyl serine, calcium, cAMP, pH and metabolic inhibitors
17. An automated continuous-flow system for the extraction and fluorometric analysis of histamine
18. 2 in rat peritoneal mast cells: Roles of cytosolic calcium and protein tyrosine kinases
19. Vancomycin-induced release of histamine from rat peritoneal mast cells and a rat basophil cell line (RBL-1)
20. Mechanisms of vancomycin-induced histamine release from rat peritoneal mast cells
21. Clinical pharmacokinetics of vancomycin
22. Phase I studies on vancomycin hydrochloride for injection
23. Vancomycin-induced histamine release and 'red man syndrome': Comparison of 1- and 2-hour infusions
24. Histamine release during rapid vancomycin administration
25. Severe reaction to vancomycin not mediated by histamine release and documented by rechallenge
26. Influence of antihistamine pretreatment on vancomycin-induced red man syndrome
27. Hemodynamic effects of rapid vancomycin infusion in critically ill patients
28. Prospective evaluation of red man syndrome in patients receiving vancomycin
29. Tryptase levels are not increased during vancomycin-induced anaphylactoid reactions
30. Characteristics of and calcium requirements for histamine release from rat peritoneal mast cells treated with concanavalin A